Create Account | Sign In: Author or Forum

News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    



Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Neurology | Nursing | Pharmacy | Psychiatry | Journal

Back to Journal Articles

Less Alzheimer’s Pathology With Angiotensin Receptor Blocker Use

Last Updated: September 11, 2012.


Autopsies show less amyloid deposition markers for angiotensin receptor blocker-treated patients

Share |

Comments: (0)



In autopsy findings, patients treated with angiotensin receptor blockers show less Alzheimer's disease-related pathology, according to a study published online Sept. 10 in the Archives of Neurology.

TUESDAY, Sept. 11 (HealthDay News) -- In autopsy findings, patients treated with angiotensin receptor blockers (ARBs) show less Alzheimer's disease (AD)-related pathology, according to a study published online Sept. 10 in the Archives of Neurology.

Ihab Hajjar, M.D., from the University of Southern California in Los Angeles, and colleagues evaluated the impact of ARB treatment on the neuropathy of AD using data from autopsy samples from 890 patients with hypertension (mean age at death, 81 years). Vascular injury markers, neuritic plaque, and neurofibrillary tangle measures were compared for those taking ARBs and those treated with other antihypertensive medications and untreated individuals.

The researchers found that participants treated with ARBs, with or without AD, showed significantly fewer amyloid deposition markers than those treated with other antihypertensive medications (lower Consortium to Establish a Registry of Alzheimer Disease score: odds ratio, 0.47; Alzheimer Disease and Related Disorders Association score: odds ratio, 0.43; Braak and Braak stage: odds ratio, 0.52; neuritic plaques: odds ratio, 0.59). Compared with untreated hypertensive patients, patients treated with ARBs also had less AD-related pathology. Participants who received ARBs had more frequent pathologic evidence of large vessel infarct and hemorrhage, as they were more likely to have had a stroke.

"This autopsy study suggests that treatment with ARBs is associated with less amyloid accumulation and AD-related pathology independent of other AD risk factors," the authors write. "To our knowledge, it is the first human evidence to suggest that treatment with ARBs may have a selective beneficial effect on amyloid metabolism."

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Previous: Gestational Diabetes, Poverty Link to ADHD Strengthened Next: SPECT/CT Associated With Improved Survival in Melanoma

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion:





Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)



Useful Sites
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.